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Abstract Cardiac resynchronization therapy has become
a standard therapy for patients who are refractory to opti-
mal medical therapy and fulfill the criteria of QRS
[120 ms, ejection fraction\35% and NYHA class II, III or
IV. Unless there is some other heretofore unrecognized
effect of pacing, the benefits of atrio-biventricular pacing
on hard outcomes observed in randomized trials can only
be attributed to the physiological changes it induces such as
increases in cardiac output and/or reduction in myocardial
oxygen consumption leading to an improvement in cardiac
function efficiency. The term ‘‘Cardiac Resynchronization
Therapy’’ for biventricular pacing presupposes that resto-
ration of synchrony (simultaneity of timing) between left
and right ventricles and/or between walls of the left ven-
tricle is the mechanism of benefit. But could a substantial
proportion of these benefits arise not from ventricular
resynchronization but from favorable shortening of AV
delay (‘‘AV optimization’’) which cannot be termed
‘‘resynchronization’’ unless the meaning of the word is
stretched to cover any change in timing, thus, rendering the
word almost meaningless. Here, we examine the evidence
on the relative balance of resynchronization and AV delay
shortening as contributors to the undoubted clinical effi-
cacy of CRT.
Keywords Atrio-ventricular optimization  CRT  Heart
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Introduction
The short-term hemodynamic effects of cardiac resyn-
chronization have been demonstrated in a number of small
studies over the last 15 years.
Cardiac resynchronization therapy has improved out-
comes of patients who have persistent substantial LV
dysfunction and/or symptoms on optimal medical therapy
and have EF\35%, QRS[120 ms and are in sinus rhythm
[1–6].
However, it is far from clear whether the beneficial
effects of CRT are a result of the inter/intra ventricular
resynchronization or a result of the shortening of the long
intrinsic AV interval, very commonly present in these
patients, or indeed a varying combination of the two.
Pathophysiology of the failing heart
Unlike a healthy heart with isolated conduction distur-
bances, in which suboptimal efficiency may impair its
function but not lead to impairment of physical capacity or
survival, the dilated failing heart may be operating on a
knife-edge in which even apparently minor inefficiency is
compounded by adverse feedback processes in a way that
impairs capacity and worsens survival. Suboptimal AV and
VV conduction are examples of such additional ineffi-
ciencies [7].
The numerous compensatory mechanisms, neurohor-
monal and mechanical, are chronically activated in heart
failure. Sympathetic tone is high and contributes the
remodeling of the myocardium which results in geometri-
cal modifications and increased wall stress.
With time, hypertrophy and/or apoptosis occur in
response to this increased stress and myocardium is
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replaced by fibrotic tissue [8]. As the function decreases
further, filling pressures rise resulting in congestion. Mitral
filling adopts a restrictive pattern [9].
Development of conduction abnormalities contributes to
this vicious cycle by regional desynchronization. The effect
of inter-atrial and inter-ventricular conduction delays is to
generate ineffective left- and right heart atrioventricular
delays. This decreases efficiency of transport of blood from
atrium to ventricle, and precipitates mitral and tricuspid
regurgitation. Interventricular conduction abnormalities
also cause paradoxical septal motion; meanwhile, extensive
intraventricular delays, such as LBBB, result in reduced
global ventricular function and impair both systolic and
diastolic behavior.
Clearly, to maximize efficiency of function, the four-
chamber heart requires not only synchrony within and
between ventricles, but also optimal atrioventricular delay.
The latter cannot rationally be termed synchrony (simul-
taneous timing) because the intention is definitely not to
have simultaneous atrial and ventricular contraction.
Although it might be argued that the ‘‘synchrony’’ should
be stretched to accommodate any change in time (not
specifically making timing simultaneous), there are two
reasons not to do so. First, such a habit, of using words to
mean their own opposite, is linguistically described as
irony and, while commonplace in politics, is an uncon-
ventional approach in science and is particularly unusual in
naming a therapy in medicine. Second, patients benefit
when clinicians understand words and concepts when they
read or hear them. When the procedure of biventricular
pacing is superseded by the (longer) name cardiac resyn-
chronization therapy, a clinician might reasonably suppose
that the newer name must have been adopted because it is
more precise, and so conclude that the purpose of the
procedure is to bring the ventricular walls into a closer
timing relationship with each other. If this turns out not to
be the dominant benefit of biventricular pacing, the choice
to impose the name ‘‘resynchronization’’ is doing patients a
disservice.
Consequence of a long AV interval and ventricular
dyssynchrony on mitral flow and effective LV filling
time
In prolonged AV conduction, mitral regurgitation can
occur in late diastole [10]. This ‘‘presystolic mitral regur-
gitation’’ was initially observed in patients with complete
heart block and normal ventricles. It occurs because atrial
systole finishes but ventricular systole does not start
immediately: this occurs whenever the AV interval is long.
Doppler echocardiography detects this atrioventricular
valve regurgitation in the last diastolic or presystolic
period, in patients with complete or first-degree heart block
[11]. Tricuspid and mitral regurgitation are equally com-
mon [12, 13].
Patients with wide QRS can also have presystolic mitral
regurgitation as a consequence of prolonged isovolumic
contraction and relaxation times. Wide QRS due to LBBB
prolongs mitral regurgitation (by sometimes over 100 ms
in patients with EF \35%) beyond that caused by a long
AV interval alone [14–17].
Impact of prolonged AV and wide QRS on ventricular
filling time
Xiao et al. cast a spotlight on left ventricular filling time in
heart failure. Prolonged AV and wide QRS each decrease
LVFT and thereby reduce stroke volume [14–17].
A prolonged AV interval reduces net volume of blood
pumped by the ventricle by 2 mechanisms. First, it allows
presystolic mitral and tricuspid regurgitation to take place,
which means that net forward flow across those valves is
smaller than it might otherwise be. Second, long AV time
causes fusion of the E and A waves reducing LVFT and
thus, cardiac output (Fig. 1).
Wide QRS (causing or worsening mechanical dyssyn-
chrony) also impairs LVFT additional to the effect of long
AV delay. Wide QRS prolongs isovolumic contraction
time (IVCT) and isovolumic relaxation time (IVRT) by
impairing the rate of rise and fall of pressure in the ven-
tricle. Since LVFT is the remnant of the RR interval after
the ‘‘bites’’ taken by ejection time (ET), IVCT and IVRT,
all three of which may be prolonged, LVFT has three
reasons to be compressed in patients with poor cardiac
timings.
Finally, long IVCT and IVRT also prolong the potential
for mitral regurgitation to occur while blood is not being
ejected forward, thus worsening the balance of blood
ejected forward versus backwards from the ventricle.
Physiological impact of shortening AV delay
by atrio-biventricular pacing
CRT can both shorten AV delay and reduce any ven-
tricular dyssynchrony. Pacing by programming the AV
delay to a shorter interval alters timing of ventricular
contraction with respect to the onset of atrial contraction
and ejection. This timing, and its effects on LVFT, has
been shown to be important [18] and it is unlikely to be
less important in patients with failing hearts. Shortening a
prolonged intrinsic AV interval by pacing, increases
ventricular preload at the onset of systole and reduces
regurgitation. This manifests as increased stroke volume
and cardiac output.
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Physiological effect of improving ventricular
dyssynchrony by atrio-biventricular pacing
Resynchronizing the ventricle should improve the con-
tractile efficiency manifesting as an increase in the rate of
change of LV pressure. This reduces IVCT and IVRT: the
time the ventricle spends achieving nothing. So on the one
hand LV filling time improves and on the other both pre-
systolic and systolic mitral regurgitation decline. These
mechanisms improve stroke volume.
The relative contributions to the increment in stroke
volume and to the ultimate clinical benefits of shortening
the AV delay versus ventricular resynchronization is cur-
rently unclear. Figures 1 and 2 are sketches illustrating the
separate effects of long AV delay and wide QRS on the
blood flow across the mitral valve during the cardiac cycle,
and how abnormalities of either or both can disturb
effective left ventricular filling time.
Effect of heart rate on LV filling time
Patients with LBBB and long intrinsic AV interval have
critically short LVFT at low heart rates [19]; LVFT,
therefore, does not significantly worsen with increasing
heart rate. Patients with a long intrinsic AV interval but
with a narrow QRS have a better LVFT for the same heart
rate. However, in these patients, with increasing heart rate
LVFT falls more dramatically and stroke volume drops
significantly [19].
So, once ventricular resynchronization has occurred, the
LVFT improves but when patients are, for example, exer-
cising and heart rate increases, the LVFT may start to fall
[19] dramatically. This rate of fall in LVFT with increasing
heart rate can be slowed down by adjusting the AV delay
(rate adaptive pacing). Although the most obvious
approach is to shorten the AV delay, interestingly, a review
[20] of the very few studies available, has suggested that
this is not universally true; in some patients, the AV delay
may need to be prolonged or left unchanged for best car-
diac output.
Nevertheless, if AV is not adjusted as the heart rate
increases, the fall of stroke volume and consequently blood
pressure becomes progressively larger [21–24].
To cast light on which of the two components of
biventricular pacing (AV optimization or ventricular
resynchronization) is more dominant in improving hemo-
dynamics and clinical endpoints, one has to look carefully
at the existing evidence from (a) small invasive studies that
assessed the acute hemodynamic benefits of CRT and
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Fig. 1 A schematic illustration combining the transmitral and aortic
flow during the cardiac cycle. To simplify understanding of Doppler
flows (left), they can be sketched wrapped into a circle, representing
the cardiac cycle, starting with atrial activation (‘‘P onset’’). The
mitral (top) and aortic (bottom) flow traces are inscribed upon inner
and outer circles, which can be combined into a single diagram
(right). This allows clear demonstration of the interaction between
timings of activation, forward flow, mitral regurgitation and isovol-
umic contraction and relaxation times (IVCT and IVRT)
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Results from acute studies
Shortening a prolonged AV interval in dilated cardiomy-
opathy by atrially sensed RV pacing was demonstrated to
be beneficial [25], long before biventricular pacing was
introduced as a mode of treatment. In patients with heart
failure and sinus tachycardia with fused E and A waves,
shortening of the AV delay during atrial-sensed RV pacing
reduced the duration of mitral and tricuspid regurgitation
and lengthened the LV filling time [26]. Shortening the AV
interval also raised exercise duration and maximum oxygen
consumption and reduced the sensation of breathlessness at
peak exercise. Another group of investigators performed
atrially sensed RV pacing in patients with severe LV
dysfunction and long intrinsic AV delays. The benefit of
AV shortening was only evident in those patients with very
prolonged intrinsic AV intervals [27].
A study that looked at the response of patients paced in
AAI and with an intrinsic wide QRS and very long AV
delays showed that atrially sensed RV pacing increased the
cardiac index by 18%, which was half as much as the
increase (35%) that atrially sensed biventricular pacing
produced at the optimal AV delay. With RV pacing, left
ventricular dyssynchrony is clearly not being corrected
(and may actually be aggravated) yet there was a signifi-
cant hemodynamic improvement suggesting that AV
shortening, in that group of patients, was responsible for
approximately 50% of the improvement [28].
The PATH-CHF [29] investigators found that shortening
AV delay of patients by with RV pacing achieved
improvements in LV dP/dtmax, Aortic SBP and pulse
pressure that were *25–50% of the improvements
achieved with full biventricular pacing. Although the
improvement in hemodynamics by RV pacing was less
than by biventricular pacing, it was far from 0, suggesting
that shortening AV delay (which is always part of biven-
tricular pacing) could contribute importantly in the hemo-
dynamic improvements seen during biventricular pacing.
Others found less convincing evidence that atrially
sensed RV pacing offers any acute benefits at all when
compared with baseline. In a study [30] of 12 patients with
narrower QRS, there was no benefit from atrially to sensed
RV pacing. However, in such patients with narrow QRS,
RV pacing induces LV dyssynchrony and therefore impairs
LV function, as demonstrated in that study. When the AV








































Fig. 2 A schematic illustration of the effects of long AV interval,
wide QRS width and biventricular pacing on stroke volume. Each
sketch shows transmitral (inner circle) and transortic (outer circle)
blood flow, with in each case atrial activation fixed in time at the top
(‘‘P’’). The top sketch illustrates blood flow in a subject with
normal AV delay and narrow QRS. A prolonged AV interval (left
sketch) delays aortic ejection thereby permitting presystolic mitral
regurgitation and delaying E wave onset resulting in fusion with the
following A wave. A wide QRS (right sketch) causes prolonged IVCT
and IVRT, reducing left ventricular filling time and worsening MR.
When prolonged AV interval and wide QRS co-exist (bottom sketch),
their effects on MR are additive and devastating. Atrio-biventricular
pacing corrects both electrical abnormalities and thereby improves
stroke volume
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in hemodynamics, with the optimal AV delay reaching the
values of the intrinsic hemodynamics: just managing to
compensate for the ventricular dyssynchrony caused by the
RV pacing.
Another group of investigators [31] reported that in
patients with wide QRS and prolonged AV delay, atrially
sensed biventricular or LV pacing showed significant
improvements in LV dP/dt max. Atrially sensed RV pac-
ing, though, it showed a trend to improved hemodynamics
(at the optimal AV delay) of approximately 30–50% of that
of biventricular pacing, this was not statistically significant.
We cannot tell from that study alone whether atrially
sensed RV pacing makes a substantial contribution, due to
a limited statistical power.
So far we have discussed the impact of atrially sensed
RV pacing versus atrially sensed biventricular/LV pacing
on acute haemodynamics in patients with EF \35%, long
intrinsic AV intervals and evidence of dyssynchrony (wide
QRS, commonly LBBB).
Looking at the effects of atrially sensed RV pacing,
which is not favorable (in fact, potentially aggravating) for
correcting ventricular dyssynchrony, can give insights of
the contribution of optimization AV delay. In the studies
above, it seems that the acute improvement by atrially
sensed RV pacing pacing at the optimal AV delay, for
example in LV dP/dtmax, can be 30–50% of that achieved
by complete biventricular pacing: AV optimization may
not be the dominant component, but neither is it trivial.
Even though in most of the invasive studies mentioned
above the optimal AV delay tended to be between 100
and 120 ms shorter than the intrinsic AV interval, assessing
the pure effect of shortening AV delay during biventricu-
lar/LV pacing is difficult. This is because during the pro-
cess of AV shortening there are, initially, changes in
the LV pre-excitation pattern and therefore ventricular
resynchronization.
The two are so closely linked that it is very difficult to
decide at which point the ‘‘ventricular resynchronization’’
is maximal and subsequent effects are purely due to AV
shortening.
In reality, both AV optimization and VV synchrony
contribute simultaneously; the relative balance is likely to
be different between patients, due to different intrinsic AV
intervals, severity of ventricular dyssynchrony, and pacing
site (RV apex/septum, LV anterior/lateral [32] etc.).
Hemodynamic curves shown in many of the studies
described above support this impression.
Whether LV and biventricular pacing are different is
less certain. In theory, appropriately timed LV pacing can
create fusion with intrinsic conduction, giving a similar
effect as biventricular pacing. If intrinsic AV delay is long,
this ideal timing of LV pacing may also be long, and so
shorter delays such as 80–100 ms might be too short,
causing the QRS to widen again, the ventricles to become
more dyssynchronous and hemodynamics to worsen [33].
As a result any benefits from AV optimization, by
shortening the AV delay may be offset by ventricular
desynchronization.
In atrially sensed biventricular pacing, however, ven-
tricular resynchronization is not dependent on intrinsic
conduction because the two pacing leads in RV and LV
mean there is less reliance on an intrinsic contribution to
activation. With biventricular pacing, greater shortening of
the AV delay can be achieved without there being an
obligatory cost of inducing ventricular dyssynchrony [34].
Do the results from the clinical trials support AV
optimization to be an important determinator of CRT
benefits?
There are no clinical trials to date allowing us to assess the
efficacy of RV DDD versus BIV DDD, in patients fulfilling
current criteria for CRT.
PACE [35], a small randomized study, of patients with
normal EF (no dyssynchrony) and with indications for
conventional dual chamber pacing, compared the effects of
atrially sensed RV versus biventricular pacing. It reported
that 50% of RV-paced patients developed dyssynchrony,
and at 6 months, RV-paced patients had an absolute reduc-
tion in ejection fraction by 7.1%, but no observed differ-
ences in functional tests, such as 6MWT and QoL (SF-36)
questionnaire, were found between RV and biventricular
pacing. However, this study was small and short, therefore
underpowered to find any true differences between arms.
More importantly, it did not address the clinical effect of AV
optimization by atrially sensed RV pacing in an already
dyssynchronous ventricle versus biventricular pacing.
In addition, larger trials such as BIOPACE and BLOCK-
HF, which will release results in the next 2–3 years, have
been recruiting similar patients to PACE, and therefore
have the same limitation.
As a result, it is not yet possible to use this approach, as
we have done with the smaller acute studies above, in order
to quantify the difference in benefits of AV optimization in
an already dyssynchronous ventricle (during atrially sensed
RV pacing) from the benefits of both AV optimization and
VV synchronization (during atrially sensed biventricular
pacing).
One other approach of assessing how important AV
optimization is versus VV synchrony is to compare the
effect of CRT in patients in AF (no AV delay to be
impaired, so pure VV resynchronization) versus patients in
SR (AV optimization with VV resynchronization). Bigger
effects of CRT in SR than in AF would suggest that in SR,
a substantial element of AV optimization is involved.
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Although there are multiple randomized controlled trials
evaluating of CRT in SR, these are lacking for AF. It is
therefore a challenge to try and establish the true benefits of
CRT in the AF population. A meta-analysis [36] of the few
prospective cohort studies looking at the effects of CRT
between AF and SR patients suggest that there is clinical
improvement in both AF and, as expected, in SR patients
when compared to baseline. However, the AF CRT group
of patients showed a relative improvement in the 6 min
walk test 50% of that of SR CRT, Minnesota quality of life
73% and NYHA class 90% of that of SR CRT.
Ejection fraction was relatively slightly higher in AF by
5%. However, the authors noted that there was a significant
degree of heterogeneity for this outcome.
One other meta-analysis [37] has also shown that the
benefit from CRT obtained by patients with SR was greater
than that obtained by patients with AF with respect to
6-MWT and quality of life. No difference in benefit was
detected between the SR and the AF patients for NYHA
class improvement or for ejection fraction.
There are, however, a number of limitations from these
meta-analyses. Selection criteria and baseline characteris-
tics of patients in different groups varied between the
studies. As much as 20% of SR patients developed AF,
who in the medically treated SR group, was not reliably
identified. Also rate control of AF patients in the CRT
group varied from just medical management to AVN
ablation.
Perhaps the most convincing evidence that SR CRT may
be superior to AF CRT comes from a subanalysis [38] of
CARE-HF. It shows the same consistent trend, albeit sta-
tistically non-significant. Some patients spontaneously
developed AF post-randomization, which was unrelated to
which arm they were randomized to. The two post hoc
groups, AF and SR, happened to have very similar baseline
characteristics, making it possible to informally compare
the effect of CRT between the AF and the SR patients. As
shown in Table 1, the AF group showed a consistent trend
to weaker effects of CRT than in SR patients. For example,
the numerical value of mortality or unplanned hospital-
ization for a cardiovascular event reduction was in AF 64%
of that of SR, emergency hospitalization from cardiovas-
cular causes 47%. Improvement of ejection fraction in AF
was 50% of that in SR, and elevation in pulse pressure was
40% of that of SR.
Predictors of response: QRS, echocardiographic
dyssynchrony or long PR?
Although, QRS width, ‘‘electrical dyssynchrony’’ is at best
a crude proxy for mechanical ventricular dyssynchrony, it
has been shown in MADIT CRT [39], REVERSE [40] and
PROSPECT [41, 42] trials to be a predictor of response to
CRT. Conversely, in the PROSPECT trial, mechanical
dyssynchrony by various echocardiographic markers was
not found to be predictor of response.
There are two potential reasons why QRS may be a
better predictor than echocardiography. Firstly, QRS width
is a simple and highly reproducible measure when carried
out automatically, whereas the echocardiographic measures
used for dyssynchrony assessment may suffer from poor
reproducibility and also from variability in methods
between test centres [41, 42].
Second, it could be argued that ventricular resynchro-
nization by pacing is an electrical intervention attempting
to reorganize electrical conduction and this occurs imme-
diately after implantation [43]. Prerequisite to success is
the presence of adequate viable myocardium and anatom-
ically suitable placement of LV pacing lead. If there is
echocardiographic evidence of ventricular dyssynchrony
but its origin is not electrical dyssynchrony, then it is
possible that pacing might be fundamentally unable to
correct the ventricular dyssynchrony.
Most trials that showed endpoint benefits of CRT used
only wide QRS as a marker of mechanical dyssynchrony
and did not require confirmation by echocardiographic
measures.
The RETHINQ trial [44], in contrast, which enrolled
patients with narrow QRS (\130 ms) but with mechanical
dyssynchrony on echocardiography, failed to show any
difference between the CRT group and the control arm.
Within this trial, patients with QRS width of 120–130 ms
had a significant benefit over the control group, compared
to the non-significant change in patients with QRS
\120 ms; strengthening the argument of using QRS for
better predicting the response of CRT, an electrical
intervention.
A sub-analysis of CARE-HF [45] also suggested that a
long intrinsic AV interval at baseline is a strong predictor
of more unfavorable outcomes and this was still the case
after 3 months of CRT. This would suggest that shortening
of intrinsic AV interval (i.e., more effective AV optimi-
zation) is coupled with more successful CRT.
Chronic studies of VV optimization
There are three studies that appear to provide data on long-
term effects of optimization of VV delay of CRT pace-
makers. However, all these studies were conducted in sinus
rhythm and therefore we do not know for certain that the
changes observed are purely due to changes in VV delay
and not from the simultaneous effects on AV delay (on one
side of the heart or the other).
First, the Decrease-HF [46] study provided a compari-
son of a fixed 0 VV delay against a VV delay determined
by a formula based on electrical measurements during
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intrinsic conduction and found that in some characteristics,
there was no difference and others, there was a trend for the
formula to give worse outcomes.
Second, the Rhythm II ICD [47] study used echocar-
diographic maximization of LVOT VTI to identify a VV
delay as optimal. No difference was found between groups,
although the study did not report whether the method of
optimization had good test–retest reproducibility. Without
confirmation that test–retest reproducibility is high, it is
very possible, given the known beat-to-beat variability of
VTI, that the allocation among VV delay settings in the
optimized group largely the play of chance rather than
identification of a true optimum setting for that patient (i.e.,
one that persists over at least a few minutes, or ideally
months). The hazards of uncritically hoping that an
apparent optimum is a consistent optimum have been
quantified recently [48].
Finally, the Insync III [49] study showed that with VV
optimization, a population of CRT patients showed a
greater increment in exercise capacity than a similar group
of historical controls (MIRACLE study), and a modest
improvement in stroke volume compared to the nominal
VV delay. In other respects including symptom class and
QoL score, there were no differences. Interestingly,
although the distribution of observed optima between
LV-first and RV-first or simultaneous remained unchanged
between the start and the end of the study, it is not reported
whether individual patients retained the same optima.
Without this information on whether patients retested had
the same optima as before, or only just drawn from the
Table 1 Calculation of the proportion of the benefit seen in sinus rhythm (SR) patients that is seen in atrial fibrillation (AF) patients, in the
CARE-HF trial








SR AF SR AF
Outcome








41 72.4 25.1 59.1 36.8 18.4 47.4
Secondary outcome of main trial, n (%)
Death from any cause 28.3 37.9 19.2 24.2 32.2 36.1 112.4








30.1 50 14.9 31.8 50.5 36.4 72.1
Continuous outcome at 18 months, mean
NYHA class 2.9 2.9 2.3 2.6 20.7 10.3 50.0
Minnesola living with
heart failure score
39.3 41.4 30.9 38.8 21.4 6.3 29.4
Variables at 18 months
Left ventricular ejection fraction, %
Median 26.4 25.9 33.7 30.1 227.7 16.2 58.6
25th and 75th
percentiles
22.2/32.3 21.6/31.0 27.7/41.7 25.3/35.3
Pulse pressure 46.7 46.6 52.2 48.8 11.8 4.7 40.1
Systolic blood pressure,
mm Hg, mean ± SD
120.1 ± 19.4 116.9 ± 20.0 126.2 ± 19.7 121.2 ± 15.4
Diastolic blood pressure,
mm Hg, mean ± SD
73.4 ± 28.8 70.3 ± 9.4 74.0 ± 10.6 72.4 ± 10.5
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same distribution, it is again unfortunately not possible to
tell whether the optimization process was identifying a
persistent feature of each individual, or drawing from a
random distribution with a mean of approximately 0.
Overall, the VV optimization trial outcomes seem
woefully unsupportive of the belief that VV timing is the
critical benefit of CRT. The only way they might be sup-
portive of an important role of VV timing is if 0 ms
(typically used as a control setting) is in fact a very good
value for most patients, and the various apparent optimi-
zation methods through being unreliable are selecting
suboptimal settings.
But even still, it is difficult to discount the precise
measurements of hemodynamic effects that have been
made during AV and VV optimization conducted in the
identical patients, which show that the AV adjustments
have many times larger an effect on blood pressure than
VV adjustments [24]. With hemodynamic techniques,
where high numbers of replicates are easily obtained, the
error bars are small. The effect of adjustment of VV delay
is therefore easily verified to be much smaller (by several
fold) than the effect of adjustment of AV delay. Neither the
VV optimization trials nor the high-precision optimization
studies, therefore, support an important role for resyn-
chronization of the ventricles as the main benefit of
biventricular pacing.
Conclusions
The direct effects of biventricular pacing are purely elec-
trical; mechanical effects occur only through myocardial
responses to activation. Meanwhile, electrical abnormali-
ties such as QRS prolongation are habitually measured
with high precision, while mechanical abnormalities are
measured with low precision (or, worse, to an unknown
precision). These two reasons act to make electrical fea-
tures of the patient intrinsically better candidates than
mechanical features, for predicting benefit of biventricular
pacing. It is therefore not surprising that electrical abnor-
malities such as long PR interval and wide QRS, which are
unambiguous to detect and change instantly with pacing,
are persistently useful predictors of benefit from CRT.
The relative contribution of AV optimization versus VV
synchronization to the overall improvement in hemody-
namics and clinical endpoints may vary between individ-
uals and may depend on QRS width and intrinsic AV
interval. These variables together with heart rate play an
important role in maximizing left ventricular filling time, a
consistent predictor of acute and long term response.
However, because of the inextricable linkage between
AV and VV timings, it is very difficult to quantify beyond
doubt the relative contribution to improvements of these
two electrical abnormalities, using standard clinical data.
From the evidence that we have seen so far and discussed
in this review, it appears that they may contribute
approximately equally. The abbreviation CRT, although,
snappy, may be doing us a disservice by focusing the mind
on resynchronization (making structures, i.e., the ventri-
cles, beat at the same time) and thereby encouraging
neglect of the powerful contribution these devices make to
AV delay adjustment.
The time may have come to abandon the above term in
favor of a neutral one. For those favoring three-letter
acronyms and neologisms to achieve a patina of sophisti-
cation, we suggest ‘‘Cardiac Euchronization Therapy’’
(CET), which recognizes that timings are being changed to
make them better, rather than necessarily synchronous.
Legitimately this can be applied to AV delay improvement
as well as ventricular resynchronization.
Alternatively, there is an older term whose meager
merits are only that it is well-known, concise and factually
correct: atriobiventricular pacing [50].
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